Cedars-Sinai

COVID-19: Study Shows Virus Can Infect Heart Cells in Lab Dish

Research, Led by Cedars-Sinai, Uses Stem Cell Technology to Learn How Coronavirus May Directly Attack Heart Muscle

Newswise — LOS ANGELES (June 30, 2020) - A new study shows that SARS-CoV-2, the virus that causes COVID-19 (coronavirus), can infect heart cells in a lab dish, indicating it may be possible for heart cells in COVID-19 patients to be directly infected by the virus. The discovery, published today in the journal Cell Reports Medicine, was made using heart muscle cells that were produced by stem cell technology. 

Although many COVID-19 patients experience heart problems, the reasons are not entirely clear. Pre-existing cardiac conditions or inflammation and oxygen deprivation that result from the infection have all been implicated. But until now, there has been only limited evidence that the SARS-CoV-2 virus directly infects the individual muscle cells of the heart.

"We not only uncovered that these stem cell-derived heart cells are susceptible to infection by novel coronavirus, but that the virus can also quickly divide within the heart muscle cells," said Arun Sharma, PhD, a research fellow at the Cedars-Sinai Board of Governors Regenerative Medicine Institute and first and co-corresponding author of the study. "Even more significant, the infected heart cells showed changes in their ability to beat after 72 hours of infection."

The study also demonstrated that human stem cell-derived heart cells infected by SARS-CoV-2 change their gene expression profile, further confirming that the cells can be actively infected by the virus and activate innate cellular "defense mechanisms" in an effort to help clear out the virus.

While these findings are not a perfect replicate of what is happening in the human body, this knowledge may help investigators use stem cell-derived heart cells as a screening platform to identify new antiviral compounds that could alleviate viral infection of the heart, according to senior and co-corresponding author Clive Svendsen, PhD.

"This viral pandemic is predominately defined by respiratory symptoms, but there are also cardiac complications, including arrhythmias, heart failure and viral myocarditis," said Svendsen, director of the Regenerative Medicine Institute and professor of Biomedical Sciences and Medicine. "While this could be the result of massive inflammation in response to the virus, our data suggest that the heart could also be directly affected by the virus in COVID-19."

Researchers also found that treatment with an ACE2 antibody was able to blunt viral replication on stem cell-derived heart cells, suggesting that the ACE2 receptor could be used by SARS-CoV-2 to enter human heart muscle cells.

"By blocking the ACE2 protein with an antibody, the virus is not as easily able to bind to the ACE2 protein, and thus cannot easily enter the cell," said Sharma. "This not only helps us understand the mechanisms of how this virus functions, but also suggests therapeutic approaches that could be used as a potential treatment for SARS-CoV-2 infection."

The study used human induced pluripotent stem cells (iPSCs), a type of stem cell that is created in the lab from a person's blood or skin cells. IPSCs can make any cell type found in the body, each one carrying the DNA of the individual. Tissue-specific cells created in this way are used for research and for creating and testing potential disease treatments.

"This work illustrates the power of being able to study human tissue in a dish," said Eduardo Marbán, MD, PhD, executive director of the Smidt Heart Institute, who collaborated with Sharma and Svendsen on the study. "It is plausible that direct infection of cardiac muscle cells may contribute to COVID-related heart disease." 

The investigators also collaborated with co-corresponding author Vaithilingaraja Arumugaswami, DVM, PhD, an associate professor of molecular and medical pharmacology at the David Geffen School of Medicine at UCLA and member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research. Arumugaswami provided the novel coronavirus that was added to the heart cells, and UCLA researcher Gustavo Garcia Jr. contributed essential heart cell infection experiments.

"This key experimental system could be useful to understand the differences in disease processes of related coronaviral pathogens, SARS and MERS," Arumugaswami said.

These studies were performed under the following approvals: UCLA provided The Human Pluripotent Stem Cell Research Oversight (hPSCRO) #2020-004-01 for Human iPSC-derived cardiac and lung cells for disease modeling COVID-19, as well as protocol BUA-2020-015-003-A approved by the UCLA Institutional Biosafety Committee (IBC). 

Funding: Research from the Svendsen laboratory has been supported by the National Institutes of Health under award number 5UG3NS105703 and the Cedars-Sinai Board of Governors Regenerative Medicine Institute. Arun Sharma is supported by an institutional training grant from the NIH under award number T32 HL116273. 

DOI: https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(20)30068-9

Read more in Discoveries Magazine: The Race to Develop a Vaccine for COVID-19

SEE ORIGINAL STUDY




Filters close

Showing results

1120 of 4595
Newswise:Video Embedded newswise-expert-panels-on-covid-19-pandemic-notable-excerpts-quotes-and-videos-available
VIDEO
Released: 19-Jan-2021 11:20 AM EST
Newswise Expert Panels on COVID-19 Pandemic: Notable excerpts, quotes and videos available
Newswise

Newswise is hosting a series of Expert Panels discussion on unique aspects of the COVID-19 pandemic. This tip sheet includes some notable quotes from the panelists.

Newswise:Video Embedded cornell-to-help-train-new-york-s-pioneering-public-health-corps
VIDEO
Released: 19-Jan-2021 10:45 AM EST
Cornell to help train New York’s pioneering public health corps
Cornell University

Cornell University is partnering with New York state and Northwell Health System to develop and train the nation’s first state public health corps, which will support COVID-19 vaccination and improve long-term public health outcomes.

Newswise: LLNL and United Kingdom company to collaborate on development of universal coronavirus vaccine
Released: 19-Jan-2021 10:10 AM EST
LLNL and United Kingdom company to collaborate on development of universal coronavirus vaccine
Lawrence Livermore National Laboratory

ConserV Bioscience Limited (CBL) and Lawrence Livermore National Laboratory (LLNL) have agreed to collaborate on the development of a broad-spectrum or “universal” coronavirus vaccine.

Newswise:Video Embedded local-covid-19-strain-found-in-over-one-third-of-los-angeles-patients2
VIDEO
Released: 19-Jan-2021 8:05 AM EST
Local COVID-19 Strain Found in Over One-Third of Los Angeles Patients
Cedars-Sinai

A new strain of the coronavirus has been found in more than one-third of COVID-19 cases in Los Angeles and may be contributing to the acceleration of the recent surge of cases across Southern California, according to new research from Cedars-Sinai.

Newswise: Lockdown affords Aussie tennis players a unique advantage
Released: 18-Jan-2021 10:05 PM EST
Lockdown affords Aussie tennis players a unique advantage
University of South Australia

Australian-based tennis players may have a once-in-a-lifetime court advantage at the 2021 Australian Open as many of their international counterparts endure lockdown restrictions in Melbourne hotels.

access_time Embargo lifts in 2 days
Embargo will expire: 21-Jan-2021 12:00 AM EST Released to reporters: 18-Jan-2021 8:05 PM EST

A reporter's PressPass is required to access this story until the embargo expires on 21-Jan-2021 12:00 AM EST The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 18-Jan-2021 5:05 PM EST
FLCCC Alliance issues public response to new NIH recommendation on the use of ivermectin
Front Line COVID-19 Critical Care Alliance (FLCCC Alliance)

The Front Line COVID-19 Critical Care Alliance (FLCCC) has issued a public response to the National Institutes of Health (NIH) regarding the NIH COVID-19 Treatment Guidelines Panel’s “neither for nor against” recommendation for the use of ivermectin in the treatment of COVID-19.

Newswise: UCLA Fielding School of Public Health Researchers Say Mask Mandates Could add $1 Trillion to the U.S. GDP
Released: 18-Jan-2021 12:05 PM EST
UCLA Fielding School of Public Health Researchers Say Mask Mandates Could add $1 Trillion to the U.S. GDP
UCLA Fielding School of Public Health

The team, including UCLA Fielding School of Public Health professors Anne Rimoin and Christina Ramirez, found that near-universal adoption of nonmedical masks in public, combined with complementary public health measures, could successfully eliminate spread of the infection. and add $1 Trillion to the U.S. GDP.

Newswise: UCLA Researcher’s Team Finds Common Blood Pressure Medications do not Increase COVID-19 Risk
Released: 18-Jan-2021 12:05 PM EST
UCLA Researcher’s Team Finds Common Blood Pressure Medications do not Increase COVID-19 Risk
UCLA Fielding School of Public Health

Dr. Marc Suchard, of the UCLA Fielding School of Public Health, co-led international research team looking at two widely used types of blood pressure drugs.


Showing results

1120 of 4595

close
1.36242